0001171843-23-000154.txt : 20230109 0001171843-23-000154.hdr.sgml : 20230109 20230109071038 ACCESSION NUMBER: 0001171843-23-000154 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230109 DATE AS OF CHANGE: 20230109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 23516536 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_010923.htm FORM 8-K Form 8-K
0000882796 False 0000882796 2023-01-09 2023-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 9, 2023

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware000-2318662-1413174
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On January 9, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2022 and providing new guidance for full year 2023 ORLADEYO net revenue and expected peak ORLADEYO sales. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023 at 6:00 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

On January 9, 2023, the Company also issued a press release announcing initial data from ongoing phase 1 single ascending dose and multiple ascending dose trials in healthy volunteers. These data support the development of BCX10013 as a potential best-in-class, once-daily, oral Factor D inhibitor for multiple complement-mediated diseases. A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 BioCryst Pharmaceuticals, Inc.
   
  
Date: January 9, 2023By: /s/ Alane Barnes        
  Alane Barnes
  Chief Legal Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)—

—ORLADEYO net revenue expected to be no less than $320 million in 2023—

—Company expects ORLADEYO peak sales of $1 billion—

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2022 and provided guidance for full year 2023 ORLADEYO net revenue and expected peak ORLADEYO sales.

“In our second year on the market we more than doubled our first year ORLADEYO sales and are more than a quarter of the way towards $1 billion in peak sales. This continues to be an exceptional launch of an oral rare disease drug and we expect this success to continue creating real value for patients and for shareholders this year and for many years to come,” said Jon Stonehouse, president and chief executive officer of BioCryst.

Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million (+53 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2022 was $251.6 million (+105 percent y-o-y).

Fourth Quarter and Full Year 2022 ORLADEYO Revenue Dynamics
“The number of patients on therapy at the end of 2022 was in-line with our expectations as patients continued to switch to ORLADEYO in the fourth quarter. Revenue in the quarter lagged our expectations slightly as we saw fewer paid product shipments based on seasonal factors and lower conversion from free to paid product than expected. We see continued growth in 2023 in the U.S. and around the world as we advance toward $1 billion in peak ORLADEYO sales,” said Charlie Gayer, chief commercial officer of BioCryst.

2023 Financial Outlook
The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. As in 2022, due to the seasonal impact of managed care reauthorizations in the first quarter of the year, the company expects revenue in the first quarter of 2023 to be similar to revenue in the fourth quarter of 2022.

Presentation Tomorrow at 41st Annual J.P. Morgan Healthcare Conference
On Tuesday, January 10, 2023 at 6:00 p.m. ET, the company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at https://www.biocryst.com/.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding preliminary, unaudited net revenue results and future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any preliminary, unaudited net revenue results and future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s completion of its customary closing, review and audit procedures for the fourth quarter and full year 2022, which may cause actual net revenue results for these periods to differ materially from the preliminary, unaudited revenue results; the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com 

 EX-99.1 3 exh_992.htm BIOCRYST REPORTS INITIAL CLINICAL DATA WITH ORAL FACTOR D INHIBITOR BCX10013 SUPPORTING DEVELOPMENT AS A ONCE-DAILY TREATMENT FOR COMPLEMENT-MEDIATED DISEASES EdgarFiling

EXHIBIT 99.2

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2—

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose. BCX10013 has been safe and generally well-tolerated at all doses studied to date. These data support the development of BCX10013 as a potential best-in-class, once-daily, oral Factor D inhibitor for multiple complement-mediated diseases.

BioCryst has initiated plans to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria (PNH), to evaluate once-daily dosing.

The company expects to confirm the optimal dosing for pivotal trials by the end of the year, move directly into a pivotal trial in patients with immunoglobulin A nephropathy (IgAN), and rapidly expand into pivotal trials in additional indications.

“We remain committed to bringing better options to patients with complement-mediated diseases and we are excited to see the immediate and durable effect of BCX10013 in suppressing the alternative pathway. Our next step is to gather data from a small number of patients, utilizing the excellent biomarkers in PNH, to quickly confirm optimal clinical dosing this year. We then plan to rapidly advance the program into pivotal trials in multiple complement-mediated diseases, beginning next year with IgAN. We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,” said Dr. Helen Thackray, chief research and development officer at BioCryst.

In the SAD assessment to date, cohorts of healthy volunteers received a single dose of 1 mg, 3 mg, 10 mg, 40 mg, 80 mg or 110 mg of oral BCX10013 or placebo. In the MAD assessment to date, cohorts of healthy volunteers received 20 mg, 40 mg or 80 mg of oral BCX10013 or placebo administered once daily for seven days (20 mg cohort) or 14 days (40 mg and 80 mg cohorts).

Following single BCX10013 dose administration, the onset of AP inhibition occurred within one hour and increased in a dose-dependent manner. At 110 mg, the highest dose studied to date, AP activity was suppressed by a mean of 97.8 percent at 24 hours post-dose. Suppression of AP activity by BCX10013 was assessed using the AP Wieslab® assay, which measures functional activity of the complement system. In the MAD studies with once-daily dosing, exposure to BCX10013 was approximately dose proportional over the studied dose range and steady-state was achieved in 7 to 14 days with modest accumulation.

Additional data from the trial can be found in slides at the investors section of the company website at www.biocryst.com.

Expanding Programs in Complement-mediated Diseases

In addition to BCX10013, which targets Factor D in the alternative pathway of complement, BioCryst is pursuing oral medicines directed at other targets across the classical, lectin and terminal pathways of the complement system, including C2, a critical upstream serine protease enzyme for activation of the classical and lectin pathways. The company has developed potent, selective molecules targeting C2, which are currently in lead optimization.

“We believe that our ability to develop oral medicines as monotherapy against targets across multiple complement pathways, in addition to the alternative pathway, could allow us to help more patients with distinctly different complement-mediated rare diseases. With our oral approach, BioCryst also has the opportunity to develop combination therapies to improve therapeutic options for those diseases affecting multiple pathways of the complement system,” Thackray added.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding our plans and expectations for our complement program and other future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; ongoing and future preclinical and clinical development of BCX10013 and other product candidates may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, may impose a clinical hold with respect to product candidates, or may withhold or delay market approval for product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

 

EX-101.SCH 4 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 6 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 09, 2023
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd., Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code 919
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 9 f8k_010923_htm.xml IDEA: XBRL DOCUMENT 0000882796 2023-01-09 2023-01-09 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2023-01-09 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_010923.htm exh_991.htm exh_992.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_010923.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_010923.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_010923.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_010923.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001171843-23-000154-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-000154-xbrl.zip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end